AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Arshad M. Khanani, MD, MA, FASRS, shares GA results from the GATHER2 extension trial during the 2025 American Academy of Ophthalmology meeting
Durga Borkar, MD, a vitreoretinal surgeon at Duke University, speaks about avacincaptad pegol for geographic atrophy treatment, the topic of her American Academy of Ophthalmology (AAO) presentation.
© 2025 MJH Life Sciences

All rights reserved.